Our leading peptide, AEM-28 has shown effectiveness in eliminating plasma cholesterol in mice models.
AEM-28 uses natural Apo E liver receptors to clear atherogenic lipoproteins.
Our Phase 2 multi-center study for AEM-28 is aimed at patients with refractory hypertriglyceridemia, including acute pancreatitis, diabetes 2 and metabolic syndrome patients.
AEM-28 binds to both lipids in the plasma and Apo E receptors in the liver.
There are no jobs at the current time